Predicting erythropoietin resistance in hemodialysis patients with type 2 diabetes

被引:16
|
作者
Schneider, Andreas [1 ,2 ]
Schneider, Markus P. [2 ,3 ]
Scharnagl, Hubert [4 ]
Jardine, Alan G. [2 ]
Wanner, Christoph [1 ]
Drechsler, Christiane [1 ]
机构
[1] Univ Hosp Wuerzburg, Div Nephrol, Dept Med, Wurzburg, Germany
[2] Univ Glasgow, Inst Cardiovasc & Med Sci, Renal Res Grp, British Heart Fdn BHF,Cardiovasc Res Ctr, Glasgow, Lanark, Scotland
[3] Univ Hosp Erlangen, Dept Nephrol & Hypertens, Erlangen, Germany
[4] Med Univ Graz, Clin Inst Med & Chem Lab Diagnost, Graz, Austria
关键词
STIMULATING AGENTS; ANEMIA; HEMOGLOBIN; PROTEIN; DISEASE;
D O I
10.1186/1471-2369-14-67
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Resistance to ESAs (erythropoietin stimulating agents) is highly prevalent in hemodialysis patients with diabetes and associated with an increased mortality. The aim of this study was to identify predictors for ESA resistance and to develop a prediction model for the risk stratification in these patients. Methods: A post-hoc analysis was conducted of the 4D study, including 1015 patients with type 2 diabetes undergoing hemodialysis. Determinants of ESA resistance were identified by univariate logistic regression analyses. Subsequently, multivariate models were performed with stepwise inclusion of significant predictors from clinical parameters, routine laboratory and specific biomarkers. Results: In the model restricted to clinical parameters, male sex, shorter dialysis vintage, lower BMI, history of CHF, use of ACE-inhibitors and a higher heart rate were identified as independent predictors of ESA resistance. In regard to routine laboratory markers, lower albumin, lower iron saturation, higher creatinine and higher potassium levels were independently associated with ESA resistance. With respect to specific biomarkers, higher ADMA and CRP levels as well as lower Osteocalcin levels were predictors of ESA resistance. Conclusions: Easily obtainable clinical parameters and routine laboratory parameters can predict ESA resistance in diabetic hemodialysis patients with good discrimination. Specific biomarkers did not meaningfully further improve the risk prediction of ESA resistance. Routinely assessed data can be used in clinical practice to stratify patients according to the risk of ESA resistance, which may help to assign appropriate treatment strategies. Clinical trial registration: The study was registered at the German medical authority (BfArM; registration number 401 3206). The sponsor protocol ID and clinical trial unique identified number was CT-981-423-239. The results of the study are published and available at http://www.ncbi.nlm.nih.gov/pubmed/16034009.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Predicting diabetes distress in patients with Type 2 diabetes: a longitudinal study
    Fisher, L.
    Mullan, J. T.
    Skaff, M. M.
    Glasgow, R. E.
    Arean, P.
    Hessler, D.
    DIABETIC MEDICINE, 2009, 26 (06) : 622 - 627
  • [32] Erythropoietin requirement in patients with type 2 diabetes mellitus on maintenance hemodialysis therapyErythropoietinbedarf bei chronisch Dialyse-behandelten Patienten mit Typ-2-Diabetes
    Georg Biesenbach
    Bernhard Schmekal
    Gabriela Eichbauer-Sturm
    Otmar Janko
    Wiener klinische Wochenschrift, 2004, 116 : 844 - 848
  • [33] Antibodies to Erythropoietin Are Associated with Erythropoietin Resistance in Hemodialysis Patients in KwaZulu-Natal (South Africa)
    Benjamin, Sherilene
    Adam, Jamila
    Krishna, Suresh Babu Naidu
    Assounga, Alain G.
    SAUDI JOURNAL OF KIDNEY DISEASES AND TRANSPLANTATION, 2020, 31 (05) : 917 - 926
  • [34] Neutrophil activation and resistance to recombinant human erythropoietin therapy in hemodialysis patients
    Costa, Elisio
    Rocha, Susana
    Rocha-Pereira, Petronila
    Nascimento, Henrique
    Castro, Elisabeth
    Miranda, Vasco
    Faria, Maria do Sameiro
    Loureiro, Alfredo
    Quintanilha, Alexandre
    Belo, Luis
    Santos-Silva, Alice
    AMERICAN JOURNAL OF NEPHROLOGY, 2008, 28 (06) : 935 - 940
  • [35] ASSOCIATION OF ERYTHROPOIETIN RESISTANCE BUT NOT HEMOGLOBIN LEVEL ITSELF WITH FATIGUE IN HEMODIALYSIS PATIENTS
    Yamasaki, Akiyo
    Yoda, Koichiro
    Koyama, Hidenori
    Yamada, Shinsuke
    Tabata, Tsutomu
    Okuno, Senji
    Okada, Shigeki
    Inaba, Masaaki
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30
  • [36] The Predictive Value of Platelet/Lymphocyte Ratio in Hemodialysis Patients With Erythropoietin Resistance
    Taymez, Dilek Guven
    Ucar, Esma
    Turkmen, Kultigin
    Ucar, Ramazan
    Afsar, Baris
    Gaipov, Abduzhappar
    Turk, Suleyman
    THERAPEUTIC APHERESIS AND DIALYSIS, 2016, 20 (02) : 118 - 121
  • [37] ACE inhibitors do not cause erythropoietin resistance in chronic hemodialysis patients
    Cruz, DN
    Mahnensmith, RL
    AbuAlfa, AA
    Perazella, MA
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1996, 7 (09): : A0976 - A0976
  • [38] Comparison of erythropoietin resistance in hemodialysis patients using calcitriol, cinacalcet, or paricalcitol
    Afsar, Baris
    Agca, Erhan
    Turk, Suleyman
    JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 55 (11): : 1280 - 1285
  • [39] Erythropoietin in Kidney Disease and Type 2 Diabetes
    Thum, Thomas
    Kalantar-Zadeh, Kamyar
    Anker, Stefan D.
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (04): : 384 - 385
  • [40] Serum Resistin as a Novel Marker of Erythropoietin Resistance in Nondiabetic Patients on Hemodialysis
    Chang, Jae Hyun
    Jung, Ji Yong
    Lee, Hyun Hee
    Chung, Wookyung
    Joo, Kwon-Wook
    Kim, Sejoong
    TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2011, 224 (04): : 281 - 285